Earnings call Eli Lilly reported Q4 2025 revenue growth of 43% YoY and full-year revenue of $65.2B (+45% YoY), with EPS up 86% to $24.21. 2026 guidance calls for $80–$83B in revenue (+25% YoY at ...
Eli Lilly (NYSE: LLY) agreed to acquire Merida Biosciences in a deal valued at up to US$2.88b to expand its immunology ...
Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875B in cash, including an upfront payment and ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
On August 31, 2026, Eli Lilly and Merida Biosciences (“Merida’) announced that they have entered into a definitive agreement for Lilly to ...
Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results